Navigation Links
DHA Hailed as Breakthrough Treatment for Lowering Risk of Developmental Disorders in Premature Infants; Animi-3(R) Prescribed to Women Who Are Not Eating Fish
Date:1/19/2009

GORDONSVILLE, Va., Jan. 19 /PRNewswire/ -- Findings published in the Journal of the American Medical Association (JAMA) have demonstrated high doses of DHA-dominant omega-3 fatty acids administered to premature infants via their mother's breast milk can reduce the risk of developmental disorders.

In a six-year study involving 657 premature infants, researchers found the lipid DHA is not developed sufficiently in premature infants, leading to possible impaired mental development. To offset this omega-3 deficiency, 1000mg DHA supplements were given to lactating mothers with pre-term infants; some infants were fed supplemental infant formula with matching DHA levels.

Approximately 50 percent fewer infants on high-DHA diets experienced delayed mental development compared to infants on low-DHA diets. Infants weighing one-third the weight of a full-term baby who were fed high-DHA diets scored better on mental development tests, with a 40 percent reduction in the incidence of mild mental delay.

"My studies have shown that pregnant and lactating women are not eating fish, which is why a pharmaceutical-grade omega-3 supplement is so important to their daily diets," said Dr. Barbara Levine, Weill Cornell Medical College. "Since women are concerned about contaminants in fish and have difficulty stomaching fish during pregnancy, many doctors are now prescribing Animi-3, a DHA-dominant omega-3 formulation, to make sure they get what they need for baby."

"This new research published in JAMA supports the reasoning behind our prescription supplement with 350mg of DHA," said President Jack Schramm, PBM Pharmaceuticals, Inc., the makers of Animi-3. "Studies continue to highlight the role nutritional deficiencies of the Animi-3 nutrients play in the overall health of adults and their children."

Women are being prescribed Animi-3 by their doctors to address DHA and other nutritional deficiencies in their diets. Each capsule of Animi-3 contains 500 mg of omega-3, (350 mg of DHA), 200 mg of phytosterols, 1 mg of folic acid, 12.5 mg of B6, and 12 mcg of B12.

More information on Animi-3 ingredients is found on www.animi-3.com and on www.dhaandbvitamins.org, a resource developed by specialists at Weill Cornell Medical College and other medical centers.

Animi-3 is not intended to diagnose, treat, or cure any disease.

Source: JAMA. 2009;301(2):175-182

    Contact:  Joe Shields
    Director of Public Relations
    (800) 959-2066 ext. 1131
    jshields@pbmproducts.com


'/>"/>
SOURCE PBM Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GRAS Proudly Announces Photometrica Version 2.0. Hailed as a Brilliant Solution for More Productive Astronomical Research by Those Engaged in Photometry Using the Global-Rent-a-scope Telescope Systems
2. Canine Cancer #1 Fear of Dog Lovers, Web Exclusive by Morris Animal Foundation Provides News on Latest Breakthroughs - Crucial Facts for Dog Owners
3. American Asthma Foundation Announces Breakthrough Discovery
4. A breakthrough in diagnosis of enteric lesions
5. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
6. DR. MIRACLES Wins 2008 WWD Beauty Biz Award: Breakthrough Product of the Year!!!
7. Res-Q Gains Rights To Market Orosine - a Breakthrough, Patented, Natural Heart Supplement That Cardiologists Are Calling the Ultimate Cardio Protection Against Heart Attacks, Strokes and Heart Failure.
8. 50th Annual Meeting of the American Society of Hematology Will Feature Breakthrough Research in Blood Diseases
9. Major North American breakthrough for dialysis patients
10. Canadian cold/flu breakthrough remedy undergoes NCI-sponsored trial in leukemia patients
11. Breakthrough in cell-type analysis offers new ways to study development and disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... Chicago, Ill., and Waycross, Ga. (PRWEB) , ... ... ... a market leader and trusted advisor within the telehealth industry, announces the company’s ... with U.S. board-certified primary care providers. Available 24 hours a day, Quick Care ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... ... ... Come to PAINWeekEnd (PWE) Tampa on May 20 and 21, at the ... 2-day program. , An attendee at a recent PAINWeekEnd said, "Very helpful, wish ... course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, presented by Dr. ...
(Date:4/24/2017)... ... 24, 2017 , ... “Reflections of God’s Work”: an enlightening collection of life ... the creation of published author, Jerri Broglin, a survivor of great loss who gained ... a great eye-opener for those searching for answers, as we are finding the answers ...
(Date:4/24/2017)... ... April 24, 2017 , ... Life of Purpose Treatment is proud to ... will be held at 7:30 pm on May 10th at the University Auditorium. , ... Sister Hazel, will support the UF Collegiate Recovery Community (UFCRC). The concert will kick ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
Breaking Medicine Technology: